Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
| Status: | Terminated |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/30/2017 |
| Start Date: | June 2009 |
| End Date: | November 2011 |
Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study
The purpose of this study is to determine if administration of pasireotide LAR for one year
to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce
the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.
to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce
the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.
Gonadotroph adenomas are the most common pituitary macroadenomas. Currently no medical
treatment as been found that decreases the size of these adenomas, so surgery is the only
treatment. The reason to think that pasireotide might affect gonadotroph adenomas is that
pasireotide binds avidly to somatostatin subtype 5 receptors, and gonadotroph adenomas
express these receptors. For this study, three subjects who have gonadotroph adenomas, as
judged by a macroadenoma of the pituitary and elevated serum FSH concentration, will be
treated with a long-acting form of pasireotide once a month for one year. The effect of
pasireotide on the size of the adenoma will be determined by MRI, and FSH secretion will be
judged by the serum concentration.
treatment as been found that decreases the size of these adenomas, so surgery is the only
treatment. The reason to think that pasireotide might affect gonadotroph adenomas is that
pasireotide binds avidly to somatostatin subtype 5 receptors, and gonadotroph adenomas
express these receptors. For this study, three subjects who have gonadotroph adenomas, as
judged by a macroadenoma of the pituitary and elevated serum FSH concentration, will be
treated with a long-acting form of pasireotide once a month for one year. The effect of
pasireotide on the size of the adenoma will be determined by MRI, and FSH secretion will be
judged by the serum concentration.
Inclusion Criteria:
- gonadotroph adenoma
Exclusion Criteria:
- visual impairment attributable to the adenoma
- radiation therapy
- active gallbladder disease
- uncontrolled diabetes
We found this trial at
1
site
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
Click here to add this to my saved trials
